Inflammation and pharmacokinetics: potential implications for HIV-infection

References

• Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med. 2000;343(1):37–49.
   PubMed Web of Science ®Google Scholar
• Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med. 2000;343(2):108–117.
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–454.
   PubMed Web of Science ®Google Scholar
• Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. Front Biosci. 1997;2:d12–26.
   PubMedGoogle Scholar
• Cressman AM, Petrovic V, Piquette-Miller M. Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. Expert Rev Clin Pharmacol. 2012;5(1):69–89.
   PubMed Web of Science ®Google Scholar
• O’Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004;350(25):2591–2602.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
   PubMed Web of Science ®Google Scholar
• Kothur K, Wienholt L, Brilot F, et al. CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: A systematic review. Cytokine. 2016;77:227–237.
   PubMed Web of Science ®Google Scholar
• Hagberg N, Ronnblom L. Systemic lupus erythematosus–a disease with a dysregulated type I interferon system. Scand J Immunol. 2015;82(3):199–207.
   PubMed Web of Science ®Google Scholar
• Mikos H, Mikos M, Obara-Moszynska M, et al. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol. 2014;65(2):150–155.
   PubMed Web of Science ®Google Scholar
• Liu M, Wu W, Sun X, et al. New insights into CD4(+) T cell abnormalities in systemic sclerosis. Cytokine Growth Factor Rev. 2016;28:31–36.
   PubMed Web of Science ®Google Scholar
• Fonseca-Camarillo G, Yamamoto-Furusho JK. Immunoregulatory pathways involved in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(9):2188–2193.
   PubMed Web of Science ®Google Scholar
• Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med. 2001;344(24):1846–1850.
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121(6):2111–2117.
   PubMed Web of Science ®Google Scholar
• Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107.
   PubMed Web of Science ®Google Scholar
• Naud J, Michaud J, Leblond FA, et al. Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos. 2008;36(1):124–128.
   PubMed Web of Science ®Google Scholar
• Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol. 2003;4(4):224–232.
   PubMed Web of Science ®Google Scholar
• Mayer-Barber KD, Sher A. Cytokine and lipid mediator networks in tuberculosis. Immunol Rev. 2015;264(1):264–275.
   PubMed Web of Science ®Google Scholar
• Schofield L, Grau GE. Immunological processes in malaria pathogenesis. Nat Rev Immunol. 2005;5(9):722–735.
   PubMed Web of Science ®Google Scholar
• Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359(14):1486–1500.
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, Giuggioli D, et al. Chemokines in the pathogenesis and as therapeutical markers and targets of HCV chronic infection, and HCV extrahepatic manifestations. Curr Drug Targets. 2015;(1389–4501).
   Google Scholar
• Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322(3):166–172.
   PubMed Web of Science ®Google Scholar
• Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol. 1990;144(2):480–484.
   PubMed Web of Science ®Google Scholar
• Chang CC, Crane M, Zhou J, et al. HIV and co-infections. Immunol Rev. 2013;254(1):114–142.
   PubMed Web of Science ®Google Scholar
• Pawlowski A, Jansson M, Skold M, et al. Tuberculosis and HIV co-infection. Plos Pathog. 2012;8(2):e1002464.
   PubMed Web of Science ®Google Scholar
• De Pablo-Bernal RS, Ruiz-Mateos E, Rosado I, et al. TNF-alpha levels in HIV-infected patients after long-term suppressive cART persist as high as in elderly, HIV-uninfected subjects. J Antimicrob Chemother. 2014;69(11):3041–3046.
   PubMed Web of Science ®Google Scholar
• Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. Aids. 2015;29(4):463–471.
   PubMed Web of Science ®Google Scholar
• Neuhaus J, Jacobs DR Jr., Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788–1795.
   PubMed Web of Science ®Google Scholar
• Vos AG, Idris NS, Barth RE, et al. Pro-inflammatory markers in relation to cardiovascular disease in HIV infection. A systematic review. Plos One. 2016;11(1):e0147484.
   PubMed Web of Science ®Google Scholar
• Beltran LM, Rubio-Navarro A, Amaro-Villalobos JM, et al. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus. Vasc Health Risk Manag. 2015;11:35–48.
   PubMedGoogle Scholar
• Hong S, Banks WA. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun. 2015;45:1–12.
   PubMed Web of Science ®Google Scholar
• Castronuovo D, Cacopardo B, Pinzone MR, et al. Bone disease in the setting of HIV infection: update and review of the literature. Eur Rev Med Pharmacol Sci. 2013;17(18):2413–2419.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Allshouse AA, Jankowski CM, et al. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013;208(2):249–259.
   PubMed Web of Science ®Google Scholar
• Freiberg MS, Bebu I, Tracy R, et al. D-dimer levels before HIV seroconversion remain elevated even after viral suppression and are associated with an increased risk of non-AIDS events. Plos One. 2016;11(4):e0152588.
   PubMed Web of Science ®Google Scholar
• Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010;55(3):316–322.
   PubMed Web of Science ®Google Scholar
• Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248–1259.
   PubMed Web of Science ®Google Scholar
• Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010;201(12):1796–1805.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203(11):1637–1646.
   PubMed Web of Science ®Google Scholar
• Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. Plos Med. 2008;5(10):e203.
   PubMed Web of Science ®Google Scholar
• Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179(4):859–870.
   PubMed Web of Science ®Google Scholar
• Grund B, Baker JV, Deeks SG, et al. Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. Plos One. 2016;11(5):e0155100.
   PubMed Web of Science ®Google Scholar
• Koethe JR, Dee K, Bian A, et al. Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retroviruses. 2013;29(7):1019–1025.
   PubMed Web of Science ®Google Scholar
• Achhra AC, Mocroft A, Reiss P, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016;17(4):255–268.
   PubMed Web of Science ®Google Scholar
• Conley LJ, Bush TJ, Rupert AW, et al. Obesity is associated with greater inflammation and monocyte activation among HIV-infected adults receiving antiretroviral therapy. Aids. 2015;29(16):2201–2207.
   PubMed Web of Science ®Google Scholar
• Petrovic V, Teng S, Piquette-Miller M. Regulation of drug transporters during infection and inflammation. Mol Interv. 2007;7(2):99–111.
   PubMedGoogle Scholar
• Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006;46:123–149.
   PubMed Web of Science ®Google Scholar
• Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol. 2005;1(4):629–640.
   PubMedGoogle Scholar
• Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36:205–216. United States
   PubMed Web of Science ®Google Scholar
• Liptrott NJ, Owen A. The role of cytokines in the regulation of drug disposition: extended functional pleiotropism? Expert Opin Drug Metab Toxicol. 2011;7(3):341–352.
   PubMed Web of Science ®Google Scholar
• Hochepied T, Berger FG, Baumann H, et al. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 2003;14(1):25–34.
   PubMed Web of Science ®Google Scholar
• Moshage HJ, Janssen JA, Franssen JH, et al. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest. 1987;79(6):1635–1641.
   PubMed Web of Science ®Google Scholar
• Beales IL, Calam J. Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut. 1998;42(2):227–234.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Bmj. 2004;329(7456):15–19.
   PubMed Web of Science ®Google Scholar
• Angamo MT, Chalmers L, Curtain CM, et al. Adverse-drug-reaction-related hospitalisations in developed and developing countries: A review of prevalence and contributing factors. Drug Saf. 2016;39(9):847–857.
   PubMed Web of Science ®Google Scholar
• Schmith VD, Foss JF. Effects of inflammation on pharmacokinetics/pharmacodynamics: increasing recognition of its contribution to variability in response. Clin Pharmacol Ther. 2008;83(6):809–811.
   PubMed Web of Science ®Google Scholar
• Chang KC, Bell TD, Lauer BA, et al. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet. 1978;1(8074):1132–1133.
   PubMed Web of Science ®Google Scholar
• Vozeh S, Powell JR, Riegelman S, et al. Changes in theophylline clearance during acute illness. Jama. 1978;240(17):1882–1884.
   PubMed Web of Science ®Google Scholar
• Renton KW, Gray JD, Hall RI. Decreased elimination of theophylline after influenza vaccination. Can Med Assoc J. 1980;123(4):288–290.
   PubMed Web of Science ®Google Scholar
• Zwillich CW, Sutton FD, Neff TA, et al. Theophylline-induced seizures in adults. Correlation with serum concentrations. Ann Intern Med. 1975;82(6):784–787.
   PubMed Web of Science ®Google Scholar
• Kraemer MJ, Furukawa CT, Koup JR, et al. Altered theophylline clearance during an influenza B outbreak. Pediatrics. 1982;69(4):476–480.
   PubMed Web of Science ®Google Scholar
• Hendeles L, Bighley L, Richardson RH, et al. Frequent toxicity from IV aminophylline infusions in critically ill patients. 1977. Ann Pharmacother. 2006;40(7–8):1417–1423.
   PubMed Web of Science ®Google Scholar
• Fleetham JA, Nakatsu K, Munt PW. Theophylline pharmacokinetics and respiratory infections. Lancet. 1978;2:898. England.
   PubMed Web of Science ®Google Scholar
• Laybourn C, Tonnesen P, Loft S, et al. Pulmonary disease and antipyrine clearance. Clin Pharmacol Ther. 1986;40(4):415–419.
   PubMed Web of Science ®Google Scholar
• Sonne J, Dossing M, Loft S, et al. Antipyrine clearance in pneumonia. Clin Pharmacol Ther. 1985;37(6):701–704.
   PubMed Web of Science ®Google Scholar
• Elin RJ, Vesell ES, Wolff SM. Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance. Clin Pharmacol Ther. 1975;17(4):447–457.
   PubMed Web of Science ®Google Scholar
• Carcillo JA, Doughty L, Kofos D, et al. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med. 2003;29(6):980–984.
   PubMed Web of Science ®Google Scholar
• Piquette-Miller M, Pak A, Kim H, et al. Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm Res. 1998;15(5):706–711.
   PubMed Web of Science ®Google Scholar
• Van Der Deen M, Marks H, Willemse BW, et al. Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients. Virchows Arch. 2006;449(6):682–688.
   PubMed Web of Science ®Google Scholar
• Turriziani O, Gianotti N, Falasca F, et al. Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. J Med Virol. 2008;80(5):766–771.
   PubMed Web of Science ®Google Scholar
• Hinoshita E, Taguchi K, Inokuchi A, et al. Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection. J Hepatol. 2001;35(6):765–773.
   PubMed Web of Science ®Google Scholar
• Chen YL, Le Vraux V, Leneveu A, et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther. 1994;55(6):649–660.
   PubMed Web of Science ®Google Scholar
• Fernandez C, Buyse M, German-Fattal M, et al. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J Pharm Pharm Sci. 2004;7(3):359–371.
   PubMed Web of Science ®Google Scholar
• Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, et al. P-glycoprotein in autoimmune diseases. Autoimmun Rev. 2004;3(3):188–192.
   PubMed Web of Science ®Google Scholar
• Kaysen GA, Dubin JA, Muller HG, et al. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int. 2004;65(4):1408–1415.
   PubMed Web of Science ®Google Scholar
• Piafsky KM, Borga O, Odar-Cederlof I, et al. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med. 1978;299(26):1435–1439.
   PubMed Web of Science ®Google Scholar
• Belpaire FM, De Smet F, Chindavijak B, et al. Effect of turpentine-induced inflammation on the disposition kinetics of propranolol, metoprolol, and antipyrine in the rat. Fundam Clin Pharmacol. 1989;3(2):79–88.
   PubMed Web of Science ®Google Scholar
• Waller DG, Smith CL, Renwick AG, et al. Intravenous propranolol in patients with inflammation. Br J Clin Pharmacol. 1982;13(4):577–578.
   PubMed Web of Science ®Google Scholar
• Bohnert T, Gan LS. Plasma protein binding: from discovery to development. J Pharm Sci. 2013;102(9):2953–2994.
   PubMed Web of Science ®Google Scholar
• Kushner I. Regulation of the acute phase response by cytokines. Perspect Biol Med. 1993;36(4):611–622.
   PubMed Web of Science ®Google Scholar
• Wigmore SJ, Fearon KC, Maingay JP, et al. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol. 1997;273(4 Pt 1):E720–6.
   PubMed Web of Science ®Google Scholar
• Gauldie J, Richards C, Harnish D, et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987;84(20):7251–7255.
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Speroff T, Ganapathi MK, et al. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol. 1991;146(9):3032–3037.
   PubMed Web of Science ®Google Scholar
• Baumann H, Richards C, Gauldie J. Interaction among hepatocyte-stimulating factors, interleukin 1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (HepG2) cells. J Immunol. 1987;139(12):4122–4128.
   PubMed Web of Science ®Google Scholar
• Campos SP, Wang Y, Koj A, et al. Insulin cooperates with IL-1 in regulating expression of alpha 1-acid glycoprotein gene in rat hepatoma cells. Cytokine. 1994;6(5):485–492.
   PubMed Web of Science ®Google Scholar
• Jiang SL, Samols D, Rzewnicki D, et al. Kinetic modeling and mathematical analysis indicate that acute phase gene expression in Hep 3B cells is regulated by both transcriptional and posttranscriptional mechanisms. J Clin Invest. 1995;95(3):1253–1261.
   PubMed Web of Science ®Google Scholar
• Rogers JT, Bridges KR, Durmowicz GP, et al. Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem. 1990;265(24):14572–14578.
   PubMed Web of Science ®Google Scholar
• Van Dijk W, Mackiewicz A. Interleukin-6-type cytokine-induced changes in acute phase protein glycosylation. Ann N Y Acad Sci. 1995;762:319–330.
   PubMed Web of Science ®Google Scholar
• Gandhi A, Moorthy B, Ghose R. Drug disposition in pathophysiological conditions. Curr Drug Metab. 2012;13(9):1327–1344.
   PubMed Web of Science ®Google Scholar
• Villarino AV, Kanno Y, Ferdinand JR, et al. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol. 2015;194(1):21–27.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36.
   PubMed Web of Science ®Google Scholar
• Prickett TD, Brautigan DL. Cytokine activation of p38 mitogen-activated protein kinase and apoptosis is opposed by alpha-4 targeting of protein phosphatase 2A for site-specific dephosphorylation of MEK3. Mol Cell Biol. 2007;27(12):4217–4227.
   PubMed Web of Science ®Google Scholar
• Leu JI, Crissey MA, Leu JP, et al. Interleukin-6-induced STAT3 and AP-1 amplify hepatocyte nuclear factor 1-mediated transactivation of hepatic genes, an adaptive response to liver injury. Mol Cell Biol. 2001;21(2):414–424.
   PubMed Web of Science ®Google Scholar
• Madonna S, Scarponi C, Sestito R, et al. The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and Kruppel-like factor-4, and it is dysregulated in psoriatic keratinocytes. J Immunol. 2010;185(4):2467–2481.
   PubMed Web of Science ®Google Scholar
• Czekaj P, Skowronek R. Transcription factors potentially involved in regulation of cytochrome P450 gene expression, topics on drug metabolism. Dr. James Paxton (Ed.), InTech, 2012. DOI: 10.5772/27817. Available from: https://www.intechopen.com/books/topics-on-drug-metabolism/transcription-factors-potentially-involved-in-regulation-of-cytochrome-p450-gene-expression
   Google Scholar
• Sui H, Fan ZZ, Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 2012;40(2):426–435.
   PubMed Web of Science ®Google Scholar
• Ferrari L, Peng N, Halpert JR, et al. Role of nitric oxide in down-regulation of CYP2B1 protein, but not RNA, in primary cultures of rat hepatocytes. Mol Pharmacol. 2001;60(1):209–216.
   PubMed Web of Science ®Google Scholar
• Ghose R, Guo T, Vallejo JG, et al. Differential role of Toll-interleukin 1 receptor domain-containing adaptor protein in Toll-like receptor 2-mediated regulation of gene expression of hepatic cytokines and drug-metabolizing enzymes. Drug Metab Dispos. 2011;39(5):874–881.
   PubMed Web of Science ®Google Scholar
• Morris SM Jr., Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol. 1994;266(6 Pt 1):E829–39.
   PubMed Web of Science ®Google Scholar
• Carlson TJ, Billings RE. Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450. Mol Pharmacol. 1996;49(5):796–801.
   PubMed Web of Science ®Google Scholar
• Sewer MB, Morgan ET. Nitric oxide-independent suppression of P450 2C11 expression by interleukin-1beta and endotoxin in primary rat hepatocytes. Biochem Pharmacol. 1997;54(6):729–737.
   PubMed Web of Science ®Google Scholar
• Monshouwer M, Witkamp RF, Nujmeijer SM, et al. Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes. Toxicol Appl Pharmacol. 1996;137(2):237–244.
   PubMed Web of Science ®Google Scholar
• Strasser SI, Mashford ML, Desmond PV. Regulation of uridine diphosphate glucuronosyltransferase during the acute-phase response. J Gastroenterol Hepatol. 1998;13(1):88–94.
   PubMed Web of Science ®Google Scholar
• Jones AE, Brown KC, Werner RE, et al. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol. 2010;66(5):475–485.
   PubMed Web of Science ®Google Scholar
• Tilton JC, Johnson AJ, Luskin MR, et al. Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons. J Virol. 2006;80(23):11486–11497.
   PubMed Web of Science ®Google Scholar
• Sereti I, Krebs S, Phanuphak N, et al. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection. Clin Infect Dis. 2017;64(2):124–131.
   PubMed Web of Science ®Google Scholar
• Castillo-Mancilla JR, Brown TT, Erlandson KM, et al. Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression. Clin Infect Dis. 2016;63(12):1661–1667.
   Google Scholar
• Ghislain M, Bastard JP, Meyer L, et al. Late antiretroviral therapy (ART) initiation is associated with long-term persistence of systemic inflammation and metabolic abnormalities. Plos One. 2015;10(12):e0144317.
   PubMed Web of Science ®Google Scholar
• Hileman CO, Kinley B, Scharen-Guivel V, et al. Differential reduction in monocyte activation and vascular inflammation with integrase inhibitor-based initial antiretroviral therapy among HIV-infected individuals. J Infect Dis. 2015;212(3):345–354.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Tran TT, Stein JH, et al. Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s. Clin Infect Dis. 2015;61(4):651–660.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Accessed February 11, 2017. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Accessed February 11, 2017. Available at: http://www.who.int/hiv/pub/arv/arv-2016/en/
   Google Scholar
• Hsu DC, Sereti I, Ananworanich J. Serious Non-AIDS events: immunopathogenesis and interventional strategies. AIDS Res Ther. 2013;10(1):29.
   PubMed Web of Science ®Google Scholar
• Kis O, Sankaran-Walters S, Hoque MT, et al. HIV-1 alters intestinal expression of drug transporters and metabolic enzymes: implications in antiretroviral drug disposition. Antimicrob Agents Chemother. 2016;60:2771–2781.
   PubMed Web of Science ®Google Scholar
• De Rosa MF, Robillard KR, Kim CJ, et al. Expression of membrane drug efflux transporters in the sigmoid colon of HIV-infected and uninfected men. J Clin Pharmacol. 2013;53(9):934–945.
   PubMed Web of Science ®Google Scholar
• Jetter A, Fatkenheuer G, Frank D, et al. Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antivir Ther. 2010;15(7):975–983.
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Lennox JL, Eaton ME, et al. Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure. J Clin Pharmacol. 2011;51(11):1539–1548.
   PubMed Web of Science ®Google Scholar
• King JR, Gerber JG, Fletcher CV, et al. Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. Aids. 2005;19(10):1059–1063.
   PubMed Web of Science ®Google Scholar
• Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS. 2008;3(3):296–305.
   PubMed Web of Science ®Google Scholar
• Barry M, Wild M, Veal G, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. Aids. 1994;8(8):F1–5.
   PubMed Web of Science ®Google Scholar
• Fletcher CV. Drug interactions should be evaluated in patients. Clin Pharmacol Ther. 2010;88(5):585–587.
   PubMed Web of Science ®Google Scholar
• Thomas SA. Drug transporters relevant to HIV therapy. J HIV Ther. 2004;9(4):92–96.
   PubMedGoogle Scholar
• Owen A, Khoo SH. Intracellular pharmacokinetics of antiretroviral agents. J HIV Ther. 2004;9(4):97–101.
   PubMedGoogle Scholar
• Bazzoli C, Jullien V, Le Tiec C, et al. Intracellular pharmacokinetics of antiretroviral drugs in hiv-infected patients, and their correlation with drug action. Clin Pharmacokinet. 2010;49(1):17–45.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Redondo R, Fryer HR, Bedford T, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016;530(7588):51–56.
   PubMed Web of Science ®Google Scholar
• Cory TJ, He H, Winchester LC, et al. Alterations in P-glycoprotein expression and function between macrophage subsets. Pharm Res. 2016;33(11):2713–2721.
   PubMed Web of Science ®Google Scholar
• Bleasby K, Castle JC, Roberts CJ, et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica. 2006;36(10-11:963–988.
   Web of Science ®Google Scholar
• Jung N, Lehmann C, Rubbert A, et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos. 2008;36(8):1616–1623.
   PubMed Web of Science ®Google Scholar
• Liptrott NJ, Khoo SH, Back DJ, et al. Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. J Immunol Methods. 2008;339(2):270–274.
   PubMed Web of Science ®Google Scholar
• Liptrott NJ, Penny M, Bray PG, et al. The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. Br J Pharmacol. 2009;156(3):497–508.
   PubMed Web of Science ®Google Scholar
• Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis. 2008;47(4):542–553.
   PubMed Web of Science ®Google Scholar
• Franceschi C, Bonafe M. Centenarians as a model for healthy aging. Biochem Soc Trans. 2003;31(2):457–461.
   PubMed Web of Science ®Google Scholar
• Schmitt V, Rink L, Uciechowski P. The Th17/Treg balance is disturbed during aging. Exp Gerontol. 2013;48(12):1379–1386.
   PubMed Web of Science ®Google Scholar
• Blaylock JM, Wortmann GW. Care of the aging HIV patient. Cleve Clin J Med. 2015;82(7):445–455.
   PubMed Web of Science ®Google Scholar
• Kulmatycki KM, Jamali F. Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. J Pharm Pharm Sci. 2005;8(3):602–625.
   PubMed Web of Science ®Google Scholar
• Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;163(3):1521–1528.
   PubMed Web of Science ®Google Scholar
• Riffo-Vasquez Y, Spina D. Role of cytokines and chemokines in bronchial hyperresponsiveness and airway inflammation. Pharmacol Ther. 2002;94(3):185–211.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867.
   PubMed Web of Science ®Google Scholar
• Kofler S, Nickel T, Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (Lond). 2005;108(3):205–213.
   PubMed Web of Science ®Google Scholar
• Almawi WY, Tamim H, Azar ST. Clinical review 103: T helper type 1 and 2 cytokines mediate the onset and progression of type I (insulin-dependent) diabetes. J Clin Endocrinol Metab. 1999;84(5):1497–1502.
   PubMed Web of Science ®Google Scholar
• Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004;25(1):4–7.
   PubMed Web of Science ®Google Scholar
• Maes M, Meltzer HY, Bosmans E, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord. 1995;34(4):301–309.
   PubMed Web of Science ®Google Scholar
• Turriziani O, Antonelli G. Host factors and efficacy of antiretroviral treatment. New Microbiol. 2004;27(2 Suppl 1):63–69.
   PubMedGoogle Scholar
• Seifert SM, Glidden DV, Meditz AL, et al. Dose Response for Starting and Stopping HIV Preexposure Prophylaxis for Men Who Have Sex With Men. Clin Infect Dis. 2015;60(5):804–810.
   PubMed Web of Science ®Google Scholar
• Eckard AR, Jiang Y, Debanne SM, et al. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209(8):1156–1164.
   PubMed Web of Science ®Google Scholar
• Scott J, Goetz MB. Human immunodeficiency virus/acquired immunodeficiency syndrome in older adults. Clin Geriatr Med. 2016;32(3):571–583.
   PubMed Web of Science ®Google Scholar
• Serrano-Villar S, Gutierrez F, Miralles C, et al. Human immunodeficiency virus as a chronic disease: evaluation and management of nonacquired immune deficiency syndrome-defining conditions. Open Forum Infect Dis. 2016;3(2):ofw097.
   PubMed Web of Science ®Google Scholar
• Gimeno-Gracia M, Crusells-Canales MJ, Armesto-Gomez FJ, et al. Polypharmacy in older adults with human immunodeficiency virus infection compared with the general population. Clin Interv Aging. 2016;11:1149–1157.
   PubMed Web of Science ®Google Scholar
• Musso CG, Belloso WH, Scibona P, et al. Impact of renal aging on drug therapy. Postgrad Med. 2015;127(6):623–629.
   PubMed Web of Science ®Google Scholar
• Annesley TM. Special considerations for geriatric therapeutic drug monitoring. Clin Chem. 1989;35(7):1337–1341.
   PubMed Web of Science ®Google Scholar
• Grant PM, Cotter AG. Tenofovir and bone health. Curr Opin HIV AIDS. 2016;11(3):326–332.
   PubMed Web of Science ®Google Scholar
• Bristol Myers Squibb. REYATAZ® (atazanavir sulfate) Capsules: Prescribing Information. Accessed February 14, 2017. Available at: https://packageinserts.bms.com/pi/pi_reyataz.pdf.
   Google Scholar
• Janssen Therapeutics. EDURANT ® (rilpivirine) tablets. Accessed February 14, 2017. Available at: https://www.janssencarepath.com/sites/www.janssencarepath.com/files/prescribing-information-edurant.pdf
   Google Scholar
• Gilead Sciences. STRIBILD ® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate). Accessed February 14, 2017. Available at: http://www.gilead.com/~/media/files/pdfs/medicines/hiv/stribild/stribild_pi.pdf
   Google Scholar
• Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses. 2003;19(9):825–835.
   PubMed Web of Science ®Google Scholar
• Gimenez F, Fernandez C, Mabondzo A. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J Acquir Immune Defic Syndr. 2004;36(2):649–658.
   PubMed Web of Science ®Google Scholar
• Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Expert Opin Drug Metab Toxicol. 2007;3(4):583–598.
   PubMed Web of Science ®Google Scholar
• ViiV Healthcare. SELZENTRY ® (maraviroc). Accessed February 14, 2017. Available at: https://www.selzentryhcp.com/
   Google Scholar
• Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS. 2012;7(5):390–400.
   PubMed Web of Science ®Google Scholar
• Molina-Arcas M, Casado FJ, Pastor-Anglada M. Nucleoside transporter proteins. Curr Vasc Pharmacol. 2009;7(4):426–434.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48(11):e108–16.
   PubMed Web of Science ®Google Scholar